Medincell's Stock Drops 3.5% and Hits the Bottom of the SBF 120 After a Brief Peak
The biotech company from Montpellier falls sharply mid-morning, after leading the SBF 120 in the previous session. The stock sinks to the bottom of the broader index, significantly diverging from the well-oriented Parisian market. This movement extends the turbulence initiated by the publication of the annual accounts last week.
A Sharp Decline that Erases Tuesday's Rebound and Brings the Stock Below Its Three Moving Averages
Medincell's stock loses 3.49% to €25.44, down from €26.36 the day before. The stock is among the biggest losers in the SBF 120, while the broader index gains 0.13% and the CAC 40 advances by 0.22%. This movement largely cancels out the 3% gain achieved on Tuesday and brings the weekly decline to 9.21%, and 6.4% over a month.
The price falls below its three moving averages, with a gap of 5.11% below the MM20 at €26.81, indicating a short-term momentum break since the 13.5% drop following the publication of the annual accounts on June 17. The RSI at 50 remains neutral, but the support at €24.08 is approaching and will be the reference zone if the selling pressure continues.
Shift Towards Recurring Revenues Still Dominates Debate After Annual Accounts
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Over 12 months, the stock is still up 48.77% and maintains a gain of 18.33% over three months, despite the recent downturn. The stock's trajectory follows the path of the annual accounts 2025/2026 published on June 17: Uzedy's royalties jumped 42% to €9.3 million, while the net loss widened to €31.3 million from €18.4 million a year earlier. During this announcement, the company highlighted the commercial launch of Olanzapine LAI expected in the fourth quarter of 2026 as the next growth driver, while warning that operating expenses would continue to rise to support expansion. The market continues to weigh the ramp-up in recurring revenues against the absence of exceptional items that had supported the previous year.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
